FDA Staff, In Briefing Documents, Says Guardant Health's Test May Fail To Detect Some Types Of Advanced Adenomas In Patients
Portfolio Pulse from Benzinga Newsdesk
FDA staff have raised concerns that Guardant Health's test may fail to detect some types of advanced adenomas in patients, according to briefing documents cited by Reuters.
May 21, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
FDA staff have raised concerns that Guardant Health's test may fail to detect some types of advanced adenomas in patients. This could impact the company's credibility and market performance.
The FDA's concerns about the efficacy of Guardant Health's test could lead to regulatory hurdles and affect investor confidence, potentially causing a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100